QQQ   282.13 (+3.14%)
AAPL   146.10 (+2.56%)
MSFT   248.88 (+3.38%)
META   140.28 (+1.20%)
GOOGL   101.64 (+3.04%)
AMZN   121.09 (+4.50%)
TSLA   249.44 (+2.90%)
NVDA   131.67 (+5.23%)
NIO   16.73 (+8.01%)
BABA   84.11 (+4.55%)
AMD   67.90 (+2.71%)
T   16.09 (+1.19%)
MU   53.96 (+4.33%)
CGC   3.14 (+7.90%)
F   12.36 (+7.76%)
GE   67.54 (+6.19%)
DIS   101.44 (+4.44%)
AMC   7.83 (+13.81%)
PYPL   92.79 (+6.43%)
PFE   44.46 (+0.72%)
NFLX   240.74 (+0.71%)
QQQ   282.13 (+3.14%)
AAPL   146.10 (+2.56%)
MSFT   248.88 (+3.38%)
META   140.28 (+1.20%)
GOOGL   101.64 (+3.04%)
AMZN   121.09 (+4.50%)
TSLA   249.44 (+2.90%)
NVDA   131.67 (+5.23%)
NIO   16.73 (+8.01%)
BABA   84.11 (+4.55%)
AMD   67.90 (+2.71%)
T   16.09 (+1.19%)
MU   53.96 (+4.33%)
CGC   3.14 (+7.90%)
F   12.36 (+7.76%)
GE   67.54 (+6.19%)
DIS   101.44 (+4.44%)
AMC   7.83 (+13.81%)
PYPL   92.79 (+6.43%)
PFE   44.46 (+0.72%)
NFLX   240.74 (+0.71%)
QQQ   282.13 (+3.14%)
AAPL   146.10 (+2.56%)
MSFT   248.88 (+3.38%)
META   140.28 (+1.20%)
GOOGL   101.64 (+3.04%)
AMZN   121.09 (+4.50%)
TSLA   249.44 (+2.90%)
NVDA   131.67 (+5.23%)
NIO   16.73 (+8.01%)
BABA   84.11 (+4.55%)
AMD   67.90 (+2.71%)
T   16.09 (+1.19%)
MU   53.96 (+4.33%)
CGC   3.14 (+7.90%)
F   12.36 (+7.76%)
GE   67.54 (+6.19%)
DIS   101.44 (+4.44%)
AMC   7.83 (+13.81%)
PYPL   92.79 (+6.43%)
PFE   44.46 (+0.72%)
NFLX   240.74 (+0.71%)
QQQ   282.13 (+3.14%)
AAPL   146.10 (+2.56%)
MSFT   248.88 (+3.38%)
META   140.28 (+1.20%)
GOOGL   101.64 (+3.04%)
AMZN   121.09 (+4.50%)
TSLA   249.44 (+2.90%)
NVDA   131.67 (+5.23%)
NIO   16.73 (+8.01%)
BABA   84.11 (+4.55%)
AMD   67.90 (+2.71%)
T   16.09 (+1.19%)
MU   53.96 (+4.33%)
CGC   3.14 (+7.90%)
F   12.36 (+7.76%)
GE   67.54 (+6.19%)
DIS   101.44 (+4.44%)
AMC   7.83 (+13.81%)
PYPL   92.79 (+6.43%)
PFE   44.46 (+0.72%)
NFLX   240.74 (+0.71%)
NASDAQ:GNFT

Genfit - GNFT Stock Forecast, Price & News

$4.04
+0.24 (+6.32%)
(As of 10/4/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.80
$4.08
50-Day Range
$3.65
$4.86
52-Week Range
$3.01
$6.38
Volume
31,871 shs
Average Volume
30,168 shs
Market Capitalization
$201.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

Genfit MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
122.8% Upside
$9.00 Price Target
Short Interest
Healthy
0.36% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.87mentions of Genfit in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.90) to ($0.10) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.94 out of 5 stars

Medical Sector

784th out of 1,087 stocks

Biological Products, Except Diagnostic Industry

129th out of 169 stocks

GNFT stock logo

About Genfit (NASDAQ:GNFT) Stock

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.

Receive GNFT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genfit and its competitors with MarketBeat's FREE daily newsletter.

GNFT Stock News Headlines

Analyzing Genfit's Short Interest - Benzinga
See More Headlines
Receive GNFT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genfit and its competitors with MarketBeat's FREE daily newsletter.

GNFT Company Calendar

Today
10/04/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GNFT
Fax
N/A
Employees
122
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+122.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$101.25 million
Cash Flow
$1.77 per share
Book Value
$2.83 per share

Miscellaneous

Free Float
N/A
Market Cap
$201.25 million
Optionable
Not Optionable
Beta
1.44

Key Executives

  • Mr. Jean-Francois Mouney (Age 67)
    Co-Founder & Chairman
    Comp: $322.08k
  • Mr. M. Pascal Prigent (Age 54)
    Chief Exec. Officer
    Comp: $488.07k
  • Prof. Bart Staels (Age 59)
    Co-Founder & Chairman of the Scientific Advisory Board
  • Mr. Thomas Baetz (Age 48)
    Chief Financial Officer
  • Mr. Pascal Caisey (Age 54)
    Chief Operating Officer
  • Dr. Dean W. Hum Ph.D. (Age 60)
    Chief Scientific Officer
  • Mr. Laurent Lannoo (Age 52)
    Corp. Sec. & Director of Legal Affairs
  • Ms. Stefanie Magner (Age 41)
    Chief Compliance Officer & VP of International Legal Affairs
  • Ms. Emilie Desodt (Age 39)
    Vice-Pres of HR
  • Mr. Jean-Christophe Marcoux (Age 45)
    Chief Strategy Officer













GNFT Stock - Frequently Asked Questions

Should I buy or sell Genfit stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Genfit in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GNFT shares.
View GNFT analyst ratings
or view top-rated stocks.

What is Genfit's stock price forecast for 2022?

3 equities research analysts have issued 1 year target prices for Genfit's stock. Their GNFT share price forecasts range from $8.00 to $10.00. On average, they expect the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 122.8% from the stock's current price.
View analysts price targets for GNFT
or view top-rated stocks among Wall Street analysts.

How have GNFT shares performed in 2022?

Genfit's stock was trading at $5.00 at the start of the year. Since then, GNFT stock has decreased by 19.2% and is now trading at $4.04.
View the best growth stocks for 2022 here
.

What is Jean-François Mouney's approval rating as Genfit's CEO?

3 employees have rated Genfit Chief Executive Officer Jean-François Mouney on Glassdoor.com. Jean-François Mouney has an approval rating of 29% among the company's employees. This puts Jean-François Mouney in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Genfit own?
When did Genfit IPO?

(GNFT) raised $132 million in an IPO on Wednesday, March 27th 2019. The company issued 5,000,000 shares at a price of $26.33 per share. SVB Leerink and Barclays served as the underwriters for the IPO and Bryan, Garnier, Natixis, Roth Capital Partners and H.C. Wainwright & Co. were co-managers.

What is Genfit's stock symbol?

Genfit trades on the NASDAQ under the ticker symbol "GNFT."

How do I buy shares of Genfit?

Shares of GNFT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Genfit's stock price today?

One share of GNFT stock can currently be purchased for approximately $4.04.

How much money does Genfit make?

Genfit (NASDAQ:GNFT) has a market capitalization of $201.25 million and generates $101.25 million in revenue each year.

How many employees does Genfit have?

The company employs 122 workers across the globe.

How can I contact Genfit?

Genfit's mailing address is PARC 885 AVENUE EUGENE AVINEE, LOOS I0, 59120. The official website for the company is www.genfit.com. The company can be reached via phone at (332) 016-4000 or via email at investors@genfit.com.

This page (NASDAQ:GNFT) was last updated on 10/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.